Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis

Cell Biochemistry and Function

Volumn 24, Issue 3, 2006, Pages 283-286

  Baskol, Gulden ^a   Baskol, Mevlut ^a   Yurci, Alper ^a   Ozbakir, Orner ^a   Yucesoy, Mehmet ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Lipid peroxidation; Malondialdehyde; Paraoxonase; Ulcerative colitis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CYTOKINE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; ULCERATIVE COLITIS;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; SERUM;

EID: 33646815663     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1224     Document Type: Article

References (33)

1. Jewell DP. 1988. Ulcerative colitis. In Sleisenger & Fordtran's Gastrointestinal and Liver Disease (6th edn), Feldman M, Scharschmidt BF, Sleisenger MH (eds). WB Saunders: Philadelphia, 1988; 1735-1739.
2. Keshavarzian A, Sedghi S, Kanofsky J, et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1992; 103; 177-185.
3. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of oxygen free metabolites in experimental colitis. Gut 1990; 31: 786-790.
4. Babs CF. Oxygen radicals in ulcerative colitis. Free Radic Biol Med 1992; 13: 169-181.
5. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal active oxygen metabolite in inflammatory bowel disease. Gastroenterology 1992; 103: 186-196.
6. Harris MI, Schiller HJ, Reilly PM, Donowitz M, Grisham MB, Bulkley GB. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenona? Pharmacol Ther 1992: 53: 375-408.
7. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98: 136-141.
8. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease. Ann NY Acad Sci 1992; 664: 103-115.
9. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994: 344: 721-724.
10. Gutteridge JM. Free radicals in disease processes: a compilation of cause and consequence. Free Radic Res Commun 1993; 19: 141-158.
11. Keshavarzian A, Banan A, Farhadi A, et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 2003; 52: 720-728.
12. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991; 91: 14-22.
13. La Du BN, Adkins CL, Kuo D, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993; 87: 25-34.
14. La Du BN. Structural and functional diversity of paraoxonases. Nature Med 1996; 2: 1186-1187.
15. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 29: 1041-1048.
17. Jewell DP. Ulcerative colitis. In Sleisenger & Fordtran's Gastrointestinal and Liver Disease (6th edn), Feldman M, Scharschmidt BF, Sleisenger MH (eds). WB Saunders: Philadelphia, 1988; 1743.
18. Jain SK. Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochim Biophys Acta 1988; 937: 205-210.
19. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.
20. Parks DA, Bulkley GB, Granger DN. Role of oxygen-derived free radicals in digestive tract disease. Surgery 1983; 94: 415-422.
21. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Intern Med 1987; 107: 526-545.
22. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6-15.
23. Blake DR, Allen RE, Lunec J. Free radicals in biological systems-a review oriented to inflammatory processes. Br Med Bull 1987; 43: 371-385.
24. Parks DA. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30: 293-298.
25. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57: 715-724.
26. Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002; 35: 569-572.
27. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 2003; 201: 28-36.
28. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol. Med 1999; 26: 892-904.
29. Kumon Y, Nakauchi Y, Suehiro T, et al. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by Hep G2. Amyloid 2002; 9: 160-164.
30. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-539.
31. Scott P. The immunology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 77-92.
32. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 1995; 96: 2758-2767.
33. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-315.